Investing.com - Clearside Biomedical (NASDAQ: CLSD) reported first quarter EPS of $-0.170, $0.03 worse than the analyst estimate of $-0.140. Revenue for the quarter came in at $230K versus the consensus estimate of $570.83K.
Clearside Biomedical's stock price closed at $1.35. It is down -4.930% in the last 3 months and up 16.380% in the last 12 months.
Clearside Biomedical saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Clearside Biomedical's stock price’s past reactions to earnings here.
According to InvestingPro, Clearside Biomedical's Financial Health score is "fair performance".
Check out Clearside Biomedical's recent earnings performance, and Clearside Biomedical's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar